Bain Capital Life Sciences

Imperative Care

Campbell

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

JENAVALVE TECHNOLOGY

Irvine

JenaValve is a medical device company focused on the design and development of innovative transcatheter heart valve solutions

ADARx Pharmaceuticals

San Diego

ADARx Pharmaceuticals, Inc., a San Diego-based clinical-stage biotechnology company, develops RNA-targeting platforms and oligonucleotide delivery technologies to inhibit, degrade, or edit disease-causing mRNA, pursuing programs across gene

Heartflow

San Francisco

Heartflow is the global leader in AI-driven coronary artery disease (CAD) management, transforming how CAD — the world’s leading cause of death — is diagnosed and treated. Our advanced technology generates personalized, precision 3D heart models from a single CT scan, providing clinicians with the clarity and confidence to deliver earlier, more effective treatments — transforming CAD into a disease that can be managed for life. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. With over 400,000 patients treated, more than 1,400 leading institutions adopting our solution, and 99.5% of U.S. lives covered — Heartflow is redefining the standard of coronary care. We're a global company, with employees across the United States, Europe and Japan. Our headquarters are in Mountain View, California, with additional offices in California, Texas, the UK and Japan. We believe CAD shouldn’t be a silent threat. We’re changing the story of CAD by making it screenable, diagnosable, and manageable — empowering clinicians to save lives and giving patients more time for what matters most.

Dicerna Pharmaceuticals

Lexington

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease.